+ T cell responses against the E6 oncoprotein of human papillomavirus (HPV) type 16 and 5 closely related members of clade A9 (HPV31, 33, 35, 52, and 58) were charted in peripheral blood mononuclear cell cultures from healthy subjects and patients who underwent HPV16 E6/E7-specific vaccination. Initial analyses with overlapping peptide arrays showed that approximately one-half of the responding subjects displayed reactivity against corresponding E6 peptides from у2 HPV types. This suggested immunological cross-reactivity and complicated retrospective evaluation of the infection history of the healthy subjects. Importantly, further dissection of the response by means of enriched and clonal T cell cultures (with protein antigen instead of peptides) revealed that CD4 + T cells that are capable of efficiently reacting against E6 antigen from multiple HPV types are rare and only occur when epitope sequences are highly conserved. Our data indicate that natural and vaccine-induced HPV16 E6-specific CD4 + T cell responses are unlikely to mediate efficient crossprotection against other clade A9 members.
CD4
+ T cell responses against the E6 oncoprotein of human papillomavirus (HPV) type 16 and 5 closely related members of clade A9 (HPV31, 33, 35, 52, and 58) were charted in peripheral blood mononuclear cell cultures from healthy subjects and patients who underwent HPV16 E6/E7-specific vaccination. Initial analyses with overlapping peptide arrays showed that approximately one-half of the responding subjects displayed reactivity against corresponding E6 peptides from у2 HPV types. This suggested immunological cross-reactivity and complicated retrospective evaluation of the infection history of the healthy subjects. Importantly, further dissection of the response by means of enriched and clonal T cell cultures (with protein antigen instead of peptides) revealed that CD4 + T cells that are capable of efficiently reacting against E6 antigen from multiple HPV types are rare and only occur when epitope sequences are highly conserved. Our data indicate that natural and vaccine-induced HPV16 E6-specific CD4 + T cell responses are unlikely to mediate efficient crossprotection against other clade A9 members.
Comparison of HPV-specific T cell immunity in patients and healthy subjects revealed that HPV16-positive cervical neoplasia is associated with failure of the CD4 + T cell response against HPV16 early antigens E6, E7, and E2. In contrast, healthy subjects commonly display strong CD4 Th1/Th2 memory responses against HPV16, bearing witness to encounter and successful immune control of this virus [1] [2] [3] [4] . The frequency at which the latter responses are detected (∼50%) is in line with the estimated lifetime incidence of HPV16 infections [5] . Our recent finding of a strong correlation between the strength of vaccine-induced HPV16 E6/ E7-specific CD4 + T cell responses and full regression of HPV16-positive lesions in patients [6] lends further support to the functional importance of CD4 T cell responses against HPV early antigens.
The existence of multiple closely related high-risk (HR) HPV types [7] , the antigens of which display up to 70% homology, suggests that a considerable degree of immunological cross-reactivity towards these viruses may exist. Increased insight in this matter is important for 2 reasons. First, this will facilitate correct interpretation of analyses of the HPV-specific T cell response in relation to health and disease, such as for assessing the role of T cell immunity in clearance of HPV infections and regression of premalignant lesions. Second, detailed information on the specificity of HR-HPVspecific T cell responses can inform us as to whether the impact of HPV-specific vaccines would be limited Figure 1 . Sequence homology between E6 antigens of human papillomavirus (HPV) clade A9. Analysis of sequence homology of E6 protein and overlapping clade A9 peptides performed in SwissProt protein database using the Basic Local Alignment Search Tool (BLAST) [24] showed 170% amino acid homology with HPV16 E6. Both percentages of identical amino acids (black bars) and percentages of amino acids with similar properties (open bars) are depicted.
to the HPV types comprised or could target a broader range of HR-HPV types. We therefore charted the incidence of CD4 + memory responses against HPV16 and highly similar HR-HPV types [8] [9] [10] in healthy donors, as well as in patients who received HPV16 E6/E7-specific vaccination. We focused on clade A9, encompassing HPV types 16, 31, 33, 35, 52, and 58, because HPV16 is the most prevalent type in cervical carcinoma and anogenital neoplasia [11, 12] . Furthermore, the degree of sequence conservation within this clade is higher than that between clades A9 and A7, the latter of which comprises HPV types 18 and 45. We choose to study responses against the E6 antigen, because its expression is associated with all stages of neoplasia, and T cell responses against E6 are found more commonly than are responses against E7 in both healthy subjects and patients [1, 4] .
MATERIALS AND METHODS

Subjects.
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy blood donors ( ), as n p 44 well as from a group ( ) of HPV16-positive patients with n p 10 high-grade vulvar intraepithelial neoplasia (VIN) who participated in our immunotherapeutic vaccination trial [6] , after informed consent.
Antigens. To examine HPV clade A9 specific T cell responses, sets of overlapping 32-mer peptides (14-amino acid overlap) spanning the entire E6 proteins of HPV16, 31, 33, 35, 52, and 58 were used (Figure 1 ). The peptides, recombinant E6 proteins, and memory response mix (MRM), consisting of a mixture of tetanus toxoid, Mycobacterium tuberculosis sonicate, and Candida albicans were produced and used as described previously [1, 2, 4, [13] [14] [15] .
T cell cultures and clones. Enriched HPV16 E6-specific T cell cultures were isolated by magnetic cell sorting (Miltenyi Biotech) based on interferon (IFN) g secretion after an extended period of in vitro stimulation, as described by de Jong et al [16] . T cell clones were isolated from the enriched HPV16 E6-specific T cell cultures using limiting dilution [13] .
Analysis of T cell responses. All analytical protocols used are part of standard operating procedures established in our laboratory, for which detailed descriptions have been published elsewhere. The presence of HPV clade A9-specific memory T cells in healthy donors and HPV16-positive patients with VIN was analyzed by IFN-g enzyme-linked immunosorbent spot NOTE. Peripheral blood mononuclear cells (PBMCs) from 30 healthy blood donors were tested against E6 peptides of HPV clade A9 (HPV16, 31, 33, 35, 52, and 58) by interferon g enzyme-linked immunosorbent spot (ELISPOT) assay. Specific spots were calculated by subtracting the mean number of spots plus 2 ϫ the standard deviation of the median control from the mean number of spots in experimental wells. The number of spots per 100,000 PBMCs are given. Antigen-specific T cell responses were considered to be positive when T cell frequencies were у1/10
4 PBMCs and at least у2 ϫ background [14] . Coinciding responses against corresponding E6 peptide pools are depicted in bold (possible crossreactivity), and responses that are not matched by coinciding reactivity against corresponding peptide pools are depicted in italics. No value is given if there was no measurable specific T cell reactivity. MRM was used as a positive control. FR, frequency of responders; MRM, memory response mix. a Definite was defined as showing an ELISPOT response towards 1 or different peptide pools of у1 HPV types. Response can, with reasonable probability, be ascribed to infection with this particular HPV type. Ambiguous was defined as ELISPOT response towards similar peptide pool of у2 HPV types. Responses can reflect the encounter of either one or both of the viruses. The total number of donors responding per HPV type is shown.
(ELISPOT) assay, as described previously [3, 4, 14, 17] . Antigenspecific T cell responses were considered to be positive when T cell frequencies were у1/10
4 PBMCs and at least у2 ϫ background.
T cell cultures and clones were tested for their specificity and function by IFN-g ELISPOT assay, intracellular cytokine staining (ICS), and in a 3-day proliferation assay. When analyzed by ICS [2, 16] , positive response was defined as at least 3 times 
the percentage of IFN-g-producing CD4 + T cells found with the medium-only control. When analyzed in 3-day proliferation assays [14, 16] , responses were defined as positive if the stimulation index (SI) was у3. Antigen-specific IFN-g secretion into the supernatant was measured by enzyme-linked immunosorbent assay or cytometric bead array (Becton Dickinson), as reported previously [1, 13] .
RESULTS
HPV clade A9 E6-specific T cell memory in healthy subjects.
Memory T cell responses to the E6 antigens of HPV clade A9 members (types 16, 31, 33, 35, 52, and 58) were evaluated in primary PBMC cultures of specimens from 30 healthy donors.
T cells responding to pools of overlapping peptides ( Figure 1 ) were enumerated by means of IFN-g ELISPOT assays. We have previously shown that these assays primarily detect CD4 + memory T cell responses [3, 4, 14, 17] . In line with the notion that a vast majority of the population encounters an HR-HPV type during their life time (80%-85% of the population [5] ), immune responses to E6 of у1 clade A9 member were detected in 19 (63%) of 30 subjects (Table 1 ). Responses to HPV16 were observed in 40% of the healthy subjects (12 of 30), in accordance with our previous studies [1, 2, 4] . Peptides recognized differed between subjects, in line with natural human leukocyte antigen (HLA) variation in the human population. Responses against E6 of the other clade A9 members were found in a smaller fraction of donors (4-9 of 30 donors). In this latter group, responses to HPV58E6 were the most prevalent (found in 9 [30%] of 30), and their frequency approximated that of responses against HPV16. As indicated in bold in Table 1 , 11 (58%) of 19 responding subjects displayed T cell responses against corresponding peptide pools from у2 clade A9 HPV types, which suggests immunological cross-reactivity. For instance, donor 15 shows reactivity against E6 peptide pool 3 of HPV16 and 33, whereas donor 26 reacts against pool 2 of HPV16 and 58. In all but 1 case (donor 28), reactivity against corresponding peptide pools was limited to 2 clade A9 members.
The patterns of HPVE6-specific responses as collected in Table 1 were used to reconstruct (with reasonable probability) the HPV clade A9 infection history for each of the donors. This was possible for 8 of 19 subjects ( 7, 19, 20 , and 27) who responded against nonmatching E6 peptide pools from 2 different HPV types. For instance, donor 7 responded to peptide pool 4 of HPV16 and peptide pools 2 and 3 of HPV58, arguing that this donor had encountered both HPV types and that the resulting E6-specific T cell responses are not crossreactive. In the remaining 11 cases, coinciding responses against corresponding peptide pools from different HPV types caused ambiguity with respect to the HPV types encountered. For instance, the reactivity by donor 4 against peptide pool 3 of HPV 31 and 52 could reflect encounter of either one or both of these viruses. Our data demonstrate that ELISPOT data shown in Table 1 cannot be readily used for retrospective evaluation of the infection history of subjects.
HPV clade A9 cross-reactivity in cultures enriched for HPV16 E6-specific T cells. We conducted a more detailed analysis with cultures enriched for HPV16 E6-specific T cells by means of magnetic cell sorting (MACS). The resulting 14 cultures (from donors 31-44) contained 2.3% (range, 0.4%-6.9%) HPV16 E6-specific T cells before and 45.6% (range, 16.5%-65.3%) HPV16 E6-specific T cells after MACS, representing a 9-60-fold enrichment. The first 10 enriched cultures were analyzed for immune responses against the different E6 antigens by IFN-g ELISPOT. The use of single peptides, rather than peptide pools, increased the resolution of the analysis. As expected on the basis of enrichment, all cultures displayed an HPV16-specific immune response against one or more peptides. Importantly, 8 of 10 cultures also responded against у 1 non-HPV16 peptide (Table 2) , which supports the notion that coincidence of T cell responses against related HPV types is a frequent event. In total, 34 HPV16 E6 peptide-specific responses were detected. Because we have used overlapping peptides, it is conceivable that many of these responses are directed against the same (overlapping) epitope (Table 2 ). In view of the latter, we can discern at least 21 distinct responses. Of these, 43% (9 of 21) are not paralleled by a response against a corresponding peptide of one of the other clade A9 members tested, strengthening the notion that these responses were primed by encounter of HPV16 (Table 2 ). In the other 57% of the cases (12 of 21), reactivity against a corresponding peptide from another HPV type was detected. In all but 2 cases (donor 31, peptide 73-104; donor 37, peptide 127-158), reactivity was limited to the corresponding peptides of HPV16 and one other clade A9 member. This indicates that, if these coinciding responses are attributable to cross-reactivity between HPV types, this cross-reactivity is not broad (see also Table 1 ).
To assess whether the coincidence of T cell responses against E6 of different HPV types reflects the reactivity of highly potent T cells, we measured the response of the 4 remaining enriched T cell cultures in the presence of peptide arrays, as well as fulllength E6 proteins. Our prior studies have shown that the repertoire of antigen-specific T cells responding to peptide-pulsed antigen-presenting cells (APCs) is generally larger than that responding to protein-pulsed APCs. We use this comparison to distinguish between highly potent T cells, which are capable of responding against limiting quantities of naturally processed antigen, and T cells that require greater quantities of cognate antigen [2, 14, 18] . Although T cells that are capable of responding against peptide-pulsed (but not protein-pulsed) APCs may reflect physiologically relevant responses, these are less likely to play a prominent role in the immune defense in case antigen presentation is suboptimal, either because of limitations in quantity or because of differences in antigen structure. Analysis of the responses by ICS allowed more-accurate comparison of the T cell fractions responding to protein and peptide antigens and, in addition, discrimination between CD4 + and CD8 + T cell responders. In accordance with our prior studies [2, 4, 19] , the latter discrimination showed that all IFN-g-producing T cells were detected in the CD4 + T cell gate, which confirmed that our methodology using long peptide or protein-pulsed APCs is geared towards detection of CD4 + T cell responses. All 4 T cell cultures responded not only to HPV16 E6 peptide but also to HPV16 E6 protein (Figure 2) , arguing that at least a major fraction of the HPV16 E6 peptide-reactive T cells reflect a potent immune response to naturally processed antigen. As expected on the basis of the data in Tables 1 and 2 , the 4 cultures also responded to E6 peptides of related HPV types. However, only one of the enriched T cell cultures responded to the matching E6 proteins ( Figure 2B ), which suggests that this culture represents a T cell response capable of reacting against HPV types 16, 31, and 35 with similar efficiency. On the basis of this criterion, the HPV16-enriched cultures of the other 3 donors, which display strong reactivity towards HPV16 E6 protein only, represent T cell responses that will readily react when encoun- b Specific spots were calculated by subtracting the mean number of spots plus 2 ϫ the standard deviation of the background from the mean number of spots in experimental wells. The number of spots per 100,000 PBMCs are given. Antigen-specific T cell responses were considered to be positive when T cell frequencies were у1/10 4 PBMCs and at least у2 ϫ background [14] . Background values for the 10 donors shown were as follows: 9, 50, 54, 90, 35, 75, 7, 27, 104, and 71, respectively. All donors show an HPV16 E6-specific response. In 8 of 10 donors, this response is matched by a response to у1 of the other clade members. With the exception of the response against peptide 37-68 (donor 36) and peptide 127-158 (donor 39), all other HPV16 E6-specific responses share potentially overlapping epitopes.
c HPV16 E6-specific responses not matched by reactivity against matching E6 peptides of the other clade members. tering HPV16 but are much less efficient against the closely related HPV types. Our findings indicate that cross-reactivity of HPV16 E6-specific T cells to 1 or 2 other HPV types, even though commonly detected in peptide pulsed cultures, occurs less often in the presence of limiting quantities of naturally processed peptide-epitopes, such as are achieved when the HPV proteins are used to stimulate the T cells. T cell cross-reactivity at the clonal level. The polyclonal T cell cultures studied thus far leave the possibility that reactivity against E6 antigens of 11 HPV type is attributable to distinct subpopulations of T cells within these cultures. We therefore examined the aspect of cross-reactivity by means of HPV-specific T cell clones isolated from the aforementioned enriched T cell culture that was reactive to E6 of HPV types 16, 31, and 35 (donor 42; Figure 2B ). Furthermore, we used shorter overlapping 10-mer peptides to minimize the possibility that reactivity would be attributable to distinct, partially overlapping epitopes encompassed by a single peptide.
In total, 73 different HPV16 peptide-reactive clones were isolated by limiting dilution, 14 of which were responsive to both HPV16 peptide and protein. In view of the likelihood of finding cross-reactivity against proteins of other HPV types, we focused our further analyses on the latter 14 clones, which were able to recognize antigen when present at limiting quantity. Clonality was confirmed by T cell receptor V-beta staining (data not shown). Clone 105 ( Figure 3A ) is an example of 1 of 7 clones that exclusively responded against peptide and protein of HPV16. Clone 20 ( Figure 3A ) is 1 of 6 clones that responded to HPV16 (peptide and protein), as well as to other clade A9 peptides, but not to the other clade A9 proteins. Only one of the clones isolated ( Figure 3A , clone 8) responded to E6 of HPV types 16, 31, and 35 at both the peptide and protein level, which suggests that efficient cross-reactivity is not only a rare event at the population level but also at the clonal level within the T cell response of a single individual.
Additional analysis of clone 8 with major histocompatibility complex class II-blocking antibodies revealed that this response was restricted by HLA-DP (data not shown). Fine mapping of the HPV16-specific immune response by means of HPV16 E6 10-mer peptides identified peptide LKFYSKISEY as the minimal epitope recognized by the T cell clone ( Figure 3B ). This epitope sequence is largely conserved between the 3 E6 proteins recognized, whereas the nonrecognized E6 proteins share a prominent tyrosine to leucine substitution at position 77 ( Figure 3C) . 
HPV clade A9 cross-reactivity in HPV16 E6/E7-vaccinated patients. A clear disadvantage of charting HR-HPV-specific
Clade A9 cross reactive T cell responses evaluated by interferon g enzyme-linked immunosorbent spot assay in peripheral blood mononuclear cells from 10 HPV16-positive patients with VIN before and after HPV16 E6/E7 peptide vaccination. Specific spots were calculated by subtracting the mean number of spots plus 2 ϫ the standard deviation of the medium control from the mean number of spots in experimental wells. The number of spots per 100,000 PBMCs are given. Antigen-specific T cell responses were considered to be positive when T cell frequencies were у1/10
4 PBMCs and at least у2 ϫ background [14] . Coinciding responses against corresponding E6 peptide pools are depicted in bold (possible crossreactivity), and responses that are not matched by coinciding reactivity against corresponding peptide pools are depicted in italics. No value is given if there was no measurable specific T cell reactivity. MRM was used as a positive control. MRM, memory response mix; PBMC, peripheral blood mononuclear cell.
a The first and last amino acid in the peptide pool used are shown.
T cell responses in healthy donors is that the HPV infection history of these subjects is unknown. As illustrated in Table 1 , this makes it difficult to causally link detection of memory T cell responses to encounter of specific HPV types. Our laboratory recently performed a phase II therapeutic vaccination study in which patients who received a diagnosis of HPV16 + vulvar intraepithelial neoplasia grade 3 (VIN-III) received 3-4 consecutive doses of a synthetic peptide vaccine encompassing the complete amino acid sequences of HPV16 E6 and E7 [6] . This study offered the unique opportunity to monitor CD4 + T cell reactivity against the E6 antigen of different clade A9 members in subjects known to have encountered both HPV16 and multiple doses of the HPV16 E6 antigen. Before vaccination, none of the patients displayed IFN-g responses against E6/E7 peptides of HPV16, in accordance with failure of this immune response, as documented in our prior studies [1, 4] . In contrast, Peripheral blood mononuclear cell (PBMC) samples of HPV16-positive patients with VIN who participated in an HPV16 E6/E7 vaccination study were isolated before the first and after the fourth vaccination. Interferon (IFN) g enzyme-linked immunosorbent spot (ELISPOT) analysis was performed against the specificed peptide pools. Responses were considered to be positive when T cell frequencies were у1/10
4 PBMCs and at least у2 ϫ the medium control value (asterisk). All patients tested ( ) displayed strong HPV16 E6-specific reactivity after vaccination (Table 3 ). In one-half n p 10 of the patients, this vaccine-induced response was also accompanied by reactivity to E6 peptides of у1 other clade A9 members (patient 4 is shown as a representative example). For the other 5 patients, the post-vaccination response was restricted to HPV16 E6 only (patient 6 is shown as a representative example).
the majority of the patients displayed HPV16-specific T cell responses, predominantly reacting against E6, after the last vaccination [6] .
For 10 of these vaccinated patients, who displayed strong HPV16-specific reactivity after vaccination, we charted T cell reactivity against E6 peptide pools from the different clade A9 members (Table 3) . In 5 patients, the vaccine-induced response against HPV16 E6 was accompanied by reactivity to E6 peptides of one or more other clade A9 members (eg, patient 4; Figure  4 ). For the other 5 patients, the post-vaccination E6-specific response was restricted to HPV16 (eg, patient 6; Figure 4) . Interestingly, the incidence by which primary PBMC cultures display reactivity against E6 peptides of both HPV16 and one or more other clade A9 members is very similar for the HPV16- Table 1 ). In 4 patients (patients 1, 7, 13, and 30), modest prevaccination responses were detected against E6 of HPV 31, 33, 35, 52, and/or 58 but not against HPV16. Notably, the detection of these prevaccination responses was not correlated with post-vaccination responses (Table 3) . Taken together, these data show that HPV16 vaccination of patients can induce IFNg responses against E6 of HPV16 and related clade A9 members independent of pre-existing immunity and that the detection of post-vaccination IFN-g responses against E6 of the related clade A9 members varies greatly between patients.
DISCUSSION
Charting of the CD4
+ memory T cell responses in healthy subjects against the E6 antigen of HPV16 and 5 closely related HR-HPV types by means of overlapping peptide arrays revealed that responders frequently display reactivity against corresponding E6 peptides from two HPV types. This initially suggested immunological cross-reactivity between the E6 antigens. However, further dissection of these responses by means of HPV16-enriched and clonal T cell cultures, as well as by using whole protein antigens, indicated that CD4 + T cells capable of reacting efficiently with limiting quantities of naturally processed E6 antigens from two or more HPV types are only rarely observed. This finding implies that natural CD4 + T cell immunity elicited through encounter of a given HR-HPV type is unlikely to provide efficient cross-protection against closely related HR-HPV types. In accordance with our data, analysis of sequential acquisition of HPV types indicated that risk of acquiring a new HPV type was not decreased among those with prior infection by a related type [20, 21] .
Our findings furthermore demonstrate that detection of memory CD4
+ T cell responses against a given HPV type cannot be readily used as an indicator that the subject concerned has encountered this particular HPV type. For 11/19 HPV-specific responders tested, the detection of responses against corresponding E6 peptides from two or more HPV types resulted in ambiguity with respect to number and identity of HPV types encountered (Table 1 ). In 6 cases (donors 13, 15, 21, 25, 26, 28), HPV16 was among the HPV types recognized. In view of the highest prevalence of HPV16, these 'overlapping' responses are most likely primed through encounter of HPV16. This notion is supported by our data showing that about half of the T cell clones reacting to peptides of HPV16 and other clade A9 members respond to HPV16-derived E6 protein only. Our data also imply that detection of CD4 + memory T cell responses by means of peptide arrays cannot readily be used for determining the prevalence of HPV types. This is expected to result in an overestimation of the prevalence of HPV types closely related to HPV16. For instance, we found HPV58 E6-specific T cell reactivity in 9/30 (30%) subjects (Table 1 ), a frequency approximating that found for HPV16 (12/30; 40%). However, HPV58 prevalence on basis of DNA testing was found to be 5-6 fold lower than that of HPV16 [22] .
With respect to our methodology of analysis, the following can be noted. First, HPV types included in our screening share more sequence homology with each other than with any of the other types. Therefore, we deem it unlikely that cross-reactivity against HPV types excluded from our study would play a significant role. Accordingly, we did not find indications for immunological cross-reactivity between E6 of HPV16 and 18 [17] . Second, it is conceivable that charting of HPV-specific immunity with single and/or shorter peptides, instead of pools comprising two 32-mer peptides, would result in fewer coinciding responses and will thereby allow for greater resolution with respect to the infection history of the subjects concerned. Notably, the larger numbers of PBMCs required for this fine mapping can generally not be obtained in the context of cohort studies.
The availability of PBMCs from HPV16 E6/E7-vaccinated patients allowed analysis of the E6-specific reactivity in subjects known to have encountered the HPV16 E6 antigen. In addition to the vaccine-induced HPV16 E6-specific T cell responses, these patients showed post-vaccination reactivity to E6 peptides from the other clade A9 members. Importantly, the overall frequency and breadth of these additional responses were not greater than those detected alongside naturally induced HPV16 E6-specific responses in healthy subjects. Our findings involving vaccinated patients strengthen the notion that the majority of coinciding responses against corresponding E6 peptides of HPV16 and one or more other clade A9 members, as found in healthy subjects, have been induced by HPV16 encounter and do not bear witness to encounter of the less-prevalent HPV types. Consequently, screening for CD4 + memory T cell responses with peptide arrays against, for example, HPV31 or HPV58 in the absence of parallel screening with a HPV16 peptide array could readily lead to misinterpretation of the resulting data. Furthermore, the resemblance between the clade A9 response pattern in healthy controls and HPV16 vaccinated patients suggests that the vaccine-induced CD4 + T cell responses are unlikely to have therapeutic impact against neoplastic lesions positive for HPV types other than HPV16. More-definitive information on the cross-reactivity of the vaccine-induced responses would require measurements of reactivity against full length antigens. Unfortunately, insufficient PBMCs were available from the vaccinated patients to perform analysis on enriched T cell cultures, whereas primary PBMC cultures are not suitable for measuring specific T cell responses against recombinant proteins because of the high background levels associated with the particular experimental setting [23] . We were therefore not able to assess whether responses against the non-HPV16 E6 peptides as recorded in the HPV16 E6/E7 vaccinated patients reflect functional, protective immunity against clade A9 members other than HPV16. However, on the basis of our current data on T cell responses from healthy subjects, we deem this unlikely.
In conclusion, in spite of considerable sequence homology between the E6 antigens of clade A9 HR-HPV types, E6-specific CD4 + T cells induced by HPV16 generally do not efficiently cross-react against the corresponding sequences of closely related HR-HPV types. In view of our findings and the similar, somewhat lower degree of sequence conservation between E7 proteins, the same is to be expected for E7-specific CD4 + T cell responses. Therefore, the therapeutic efficacy of vaccines comprising E6 and E7 antigens of a given HR-HPV type is likely to be limited to anogenital lesions positive for the specific HR-HPV type concerned.
